AQR Arbitrage LLC Decreases Holdings in Abrdn Life Sciences Investors (NYSE:HQL)

AQR Arbitrage LLC reduced its position in Abrdn Life Sciences Investors (NYSE:HQL) by 28.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 188,425 shares of the company’s stock after selling 74,853 shares during the period. AQR Arbitrage LLC owned about 0.69% of Abrdn Life Sciences Investors worth $2,472,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HQL. Janney Montgomery Scott LLC lifted its holdings in shares of Abrdn Life Sciences Investors by 7.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 91,398 shares of the company’s stock valued at $1,199,000 after purchasing an additional 6,200 shares in the last quarter. Kingswood Wealth Advisors LLC acquired a new position in shares of Abrdn Life Sciences Investors during the 4th quarter worth approximately $160,000. Absolute Investment Advisers LLC purchased a new stake in Abrdn Life Sciences Investors in the 4th quarter valued at approximately $5,242,000. Wolverine Asset Management LLC acquired a new stake in Abrdn Life Sciences Investors during the 4th quarter valued at $1,594,000. Finally, BankPlus Trust Department acquired a new stake in Abrdn Life Sciences Investors during the 4th quarter valued at $28,000. 32.21% of the stock is owned by institutional investors and hedge funds.

Abrdn Life Sciences Investors Price Performance

NYSE HQL opened at $12.73 on Friday. Abrdn Life Sciences Investors has a fifty-two week low of $10.55 and a fifty-two week high of $15.90. The business has a fifty day moving average of $12.50 and a 200-day moving average of $13.55.

Abrdn Life Sciences Investors Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Friday, February 21st were paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 14.77%. The ex-dividend date of this dividend was Friday, February 21st.

Insider Buying and Selling at Abrdn Life Sciences Investors

In other Abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. sold 1,846 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $14.03, for a total value of $25,899.38. Following the completion of the transaction, the insider now directly owns 3,379,525 shares in the company, valued at approximately $47,414,735.75. The trade was a 0.05 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 253,805 shares of company stock worth $3,231,105. Corporate insiders own 10.06% of the company’s stock.

Abrdn Life Sciences Investors Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.